ArticleInternational journal of colorectal disease2025
The impact of nano-carbon suspension lymph node tracing on rectal cancer surgery post-neoadjuvant therapy.
Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of Nano-Carbon Tracing Versus Indocyanine Green in Lymph Node Detection for Minimally Invasive Colorectal Resection.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the impact of using nano-carbon suspension for lymph node tracing on the number of detected lymph nodes and short-term clinical outcomes in patients undergoing laparoscopic radical resection for rectal cancer following neoadjuvant therapy.
methodsThis study retrospectively analyzed clinical data from 109 patients who underwent neoadjuvant therapy and laparoscopic radical resection for rectal cancer at Weifang People's Hospital from January 2020 to December 2022. Of these, 43 patients received an endoscopic submucosal injection of nano-carbon suspension (experimental group), with 22 patients receiving the injection before neoadjuvant therapy and 21 patients receiving it 24 h before surgery. The remaining 66 patients did not receive the nano-carbon injection (control group). All patients received neoadjuvant therapy according to guidelines and were operated on by the same surgical team. By comparing the number of detected lymph nodes and short-term clinical outcomes among the three groups, the study aimed to investigate the impact of the endoscopic submucosal injection of nano-carbon and the timing of injection on the surgical quality for patients with rectal cancer undergoing neoadjuvant therapy.
resultsThe number of detected lymph nodes in the groups injected with nano-carbon before neoadjuvant therapy and 24 h before surgery was significantly higher than that in the non-injected group (P = 0.000), with a significant increase in the proportion of detecting ≥ 12 lymph nodes (P = 0.016), showing statistical significance. There is no statistically significant difference in the number of detected lymph nodes between the group injected with nano-carbon before neoadjuvant therapy and the group injected 24 h before surgery (P = 0.141).
conclusionsEndoscopic submucosal injection of nano-carbon suspension for lymph node tracing can increase the number of detected lymph nodes in rectal cancer surgery following neoadjuvant therapy, enabling more precise postoperative tumor staging. Although pre-neoadjuvant nano-carbon injection yielded a numerically higher lymph-node detection rate, this trend was not statistically significant (P = 0.141). Consequently, the optimal injection timing remains unconfirmed and should be validated in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.